Science for just $15 USD. Pursuing promising candidates for PAH Endothelial cells and smooth muscle cells are dysfunctional in pulmonary arterial hypertension (PAH). Gu et al. used transcriptomics and induced pluripotent stem cell–derived endothelial cells from patients with PAH to identify a tyrosine kinase inhibitor, tyrphostin-AG1296, that improved survival of cells. AG1296 activated bone morphogenetic protein receptor signaling and limited the proliferation of PAH smooth muscle cells, and its drug signature correlated with an anti-PAH gene signature. Treatment of a rat model of pulmonary hypertension reversed vascular remodeling and AG1296-induced regression of lesions in lung organ cultures ex vivo. Combining transcriptomics with functional cell assays could accelerate identification of drug candidates for PAH.